Breast Cancer Features Archive
Women with BRCA 1/2 mutations have lower ovarian reserve and experience greater ovarian reserve loss after chemotherapy compared with those who are BRCA wild-type.
Whole-exome sequencing at standard depths of coverage is prone to technical noise and false positives, researchers reported.
In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody CTLA-4; DMabs may one day rival traditional mAbs.
Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.
Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.
Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.
Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.
High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.
Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.
By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.
Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.
A change in diagnosis was often the result of review by a multidisciplinary tumor board at the NCI-designated cancer center.
Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.
Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.
Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.
A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.
Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.
Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.
Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.
Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Having a high body mass index reduces the risk for developing breast cancer before menopause, but more research is needed to understand the biological mechanism.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
Higher ERDP scores were significantly associated with developing breast cancer.
Preventive treatments are strongly recommended in women with AH and LCIS.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
It is unclear whether breast cancer screening — and specifically mammography — reduces the likelihood of being diagnosed with advanced-stage disease.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
Phase 1 trials should be considered therapeutic options for some patients.
The risk should not discourage patients with cancer from taking these potentially life-extending therapies.
While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.
To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it's unclear if and when artificial intelligence will be integrated into clinical practice.
While APHINITY showed a small improvement with adjuvant pertuzumab, it is unclear whether the benefits are worth the cost, time, and toxicity associated with the drug.
There is no evidence that women at high risk of breast cancer, such as those who harbor BRCA1 or BRCA2 mutations, should avoid hormonal contraception.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Treatment advances over recent years render much of the previously used evidence outdated.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
As breast cancer can be asymptomatic or have a series of different symptoms and physical exam findings, standard procedure is hard to define.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.
NPS with electrodes is under investigation as a potential new ablative — and possibly immunotherapeutic — cancer treatment modality.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerging agents and combinations being studied in ongoing clinical trials.
Since the discovery of the notch pathway 25 years ago, several studies have found a link between different Notch receptors and specific forms of breast cancer, including triple-negative.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps
Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.
CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.
While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.
The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.
Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.
The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.
Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.
The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.
Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.
Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.
Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.
Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.
Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.
Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.
The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.
Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of care for women with early breast cancer — remains uncertain.
Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.
If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?
Researchers found that, among men previously treated for lymphoma, the incidence of breast cancer is higher than in the general population.
Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.
While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.
Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.
More prospective studies are needed to determine the role of diet and the underlying mechanisms that explain dietary benefits among women with breast cancer.
According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.
According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC